1. Touitou I, Galeotti C, Rossi-Semerano L, Hentgen V, Piram M, Kone-Paut I. The expanding spectrum of rare monogenic autoinfl ammatory diseases. Orphanet J Rare Dis. 2013;8:162. doi:10.1186/1750−1172−8-162.
2. Федоров ЕС, Салугина СО, Кузьмина НН. Аутовоспалительные синдромы: что необходимо знать ревматологу. Современная ревматология. 2012;6(2): 49−59. [Fedorov ES, Salugina SO, Kuz’mina NN. Autoinfl ammatory syndromes: What a rheumatologist should know. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012;6(2):49−59. (In Russ.)]. doi: 10.14 412/1996−7012−2012−728
3. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797−807. doi: 10.1016/s0092−8674(00)80539−5.
4. French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25−31. doi: 10.1038/ng0997−25.
5. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227−253. doi: 10.1016/0002−9343(67)90167−2.
6. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644−651. doi: 10.1136/annrheumdis-2015−208 690.
7. Goldfi nger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302. doi: 10.1056/NEJM197212212872514.
8. Dinarello CA, Wolff SM, Goldfi nger SE, et al. Colchicine therapy for familial mediterranean fever. A doubleblind trial. N Engl J Med. 1974;291(18):934−937. doi: 10.1056/NEJM197410312911804.
9. Kallinich T, Haff ner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119:e474−483. doi:10.1542/peds.2006−1434.
10. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10): 1879−1885. doi: 10.1002/art.1 780 401 023.
11. Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998;27(2):92−97. doi: 10.1080/30 097 498 440 949.
12. Костик М. М., Жогова О. В., Лагунова Н. В., Ивановский С. В., Колобова О. Л., Мельникова Л. Н. Семей- ная средиземноморская лихорадка: современные подходы к диагностике и лечению. Вопросы современной педиатрии. 2018; 17 (5): 371−380. doi: 10.15 690/vsp.v17i5.1953)
13. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516−518. doi: 10.3899/jrheum.100 718.
14. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24(4):435−437.
15. Hashkes P, Spalding SJ, Giannini EH, et al. Rilonacept for colchicines-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533−541. doi:10.7326/0003−4819−157−8-201 210 160−3.
16. De Benedetti F, Anton J, Ben-Chetrit E, et al. Effi cacy and safety of canakinumab in patients with periodic fever syndromes (colchicine-resistant FMF, HIDS/MKD and TRAPS): results from a Phase 3, Pivotal, Umbrella Trial. Arthritis Rheumatol. 2016;68 (Suppl 10):3205.